EMERYVILLE, Calif.–(BUSINESS WIRE)–Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the upcoming poster presentation of new preclinical data for its lead therapeutic candidate, NTX-0250, which targets human papillomavirus (HPV)-driven cancers. The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), being held in Boston, MA, from November 8-12, 2022.
The poster presentation will showcase data that demonstrates that NTX-0250, a multimodal, mRNA-based therapeutic, is capable of inducing the complete regression of large murine tumors. The details about the presentation and session information are as follows:
Title: NTX-0250, a multimodal mRNA-based immunotherapy, eradicates large established tumors in a stringent mouse model of HPV16-driven cancer.
Abstract Number: 1084
Presentation Session: Immune-stimulants and immune modulators
Presentation Date and Time: Friday, Nov. 11, 2022, 11:55–1:25 p.m. and Poster Reception (7–8:30 p.m.)
Lead Author: Ole A.W. Haabeth
Poster presentations will be accessible in person and virtually. All accepted abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Nov. 7 at 8 a.m. EST. For more information about the 37th SITC annual meeting, please visit https://www.sitcancer.org/home.
About Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker’s technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.
For more information, visit www.nutcrackerx.com.
Contacts
Geir Falck-Pedersen
HDMZ
Nutcrackerpr@hdmz.com
(773) 901-0145